Biotronik’s Orsiro Stent Beats Abbott’s Xience In BIOSTEMI Trial
Acute ST-elevation myocardial infarction patients treated with Biotronik’s Orsiro biodegradable polymer sirolimus-eluting stent had a significantly lower rate of target vessel failure than patients treated with Abbott’s Xience durable polymer everolimus-eluting stent at the one-year follow-up in the BIOSTEMI trial.
You may also be interested in...
Biotronik is touting successful clinical trial results with its Orsiro sirolimus-eluting coronary stent while continuing to develop a resorbable stent.
In an interview with Medtech Insight, Biotronik president Ryan Walters explained why the former Mayo Clinic cardiologist was the right choice to be the first CMO in the company's history and David Hayes discussed his reasons for taking the job.
Results Recap: CRT In DC Features New Biotronik Stent Data, Encouraging TAVR Low-Risk Data; Ablative Systems’ Alcohol Renal Denervation
Medtech Insight's Results Recap covers major device trial results appearing on MedDeviceTracker. This week's edition, covering March 1 to March 7, includes results of late-breaking trials presented at the 2019 Cardiovascular Research Technologies (CRT) conference in Washington, DC, including new data supporting Biotronik’s biodegradable polymer sirolimus-eluting stent and the company’s resorbable magnesium stent, results of the LRT trial of transcatheter aortic valves in low-risk patients, plus promising clinical data supporting Ablative System’s alcohol renal-denervation system.